Physician profile
Albert E Germain
NPI 1841236122
$2,931.70
in general payments reported to CMS, 2019-2025
14 companies · $24.82 in 2025
The $24.82 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $209 · 2021: $124 · 2022: $704 · 2023: $769 · 2024: $312 · 2025: $24.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $756.46 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $465.73 | 2022-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $404.92 | 2019-2021 | |
| Allergan, INC. | $401.39 | 2019-2022 | |
| Alcon Vision LLC | $264.56 | 2019-2025 | Precision 1, Precision7 |
| Shire North American Group INC | $166.92 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $160.27 | 2019-2024 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $124.97 | 2024 | Xdemvy |
| Coopervision INC. | $72.75 | 2019-2022 | |
| Abbvie INC. | $46.04 | 2022-2024 | |
| Sight Sciences, INC. | $19.73 | 2022 | |
| Harrow Eye, LLC | $17.93 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $16.95 | 2022 | |
| Abb Con-Cise Optical Group LLC | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Germain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.